Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 10, Number 9—September 2004


SARS Antibody Test for Serosurveillance

Po-Ren Hsueh*1, Chuan-Liang Kao*1, Cun-Nan Lee*, Li-Kuan Chen†, Mei-Shian Ho‡, Charles Sia§¶, Xin De Fang§, Shugene Lynn¶, Tseng Yuan Chang§, Shi Kau Liu§, Alan M. Walfield§, and Chang Yi Wang§¶Comments to Author 
Author affiliations: *National Taiwan University College of Medicine, Taipei, Taiwan; †Tsu Chi University, Hualien, Taiwan; ‡Academia Sinica, Taipei, Taiwan; §United Biomedical, Inc., Hauppauge, New York, USA; ¶United Biomedical, Inc. Asia, Hsin Chu, Taiwan; 1Drs. Hsueh and Kao contributed equally to this article.

Main Article

Table 2

Sensitivity and specificity of peptide-based ELISAa

Source of samples Total no. ELISA+ ELISA–
Blood donors (Gulf Coast Regional Blood Bank, USA) 1,390 0 1,390
Blood-transmitted pathogen panel (various blood banks, USA) 52 0 52
Interference panel (BBI) 41 0 41
Confirmed SARS (TW CDC) 69 69 0
Influenza patients (NTU) 10 0 10
Influenza vaccinees (NTU) 16 0 16
Rubella patients (NTU) 10 0 10
EBV patients (NTU) 9 0 9
Mycoplasma (NTU) 5 0 5
CMV patients (NTU) 8 0 8

aELISA, enzyme-linked immunosorbent assay; NTU, National Taiwan University; BBI, Boston Biomedica Inc (Boston, MA); TW CDC, Taiwan Center for Disease Control; CMV, cytomegalovirus; EBV, Epstein-Barr virus.

Main Article